Mansoor Husain

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4186729/publications.pdf

Version: 2024-02-01

133 papers	13,320 citations	41344 49 h-index	22832 112 g-index
135 all docs	135 docs citations	135 times ranked	16998 citing authors

#	Article	IF	Citations
1	MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes. Cardiovascular Diabetology, 2022, 21, 31.	6.8	31
2	Irx5 and transient outward K⁺ currents contribute to transmural contractile heterogeneities in the mouse ventricle. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 322, H725-H741.	3.2	1
3	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovascular Diabetology, 2022, 21, 64.	6.8	4
4	Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke, 2022, 53, 2749-2757.	2.0	30
5	Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation, 2022, 146, 808-818.	1.6	33
6	Applying <scp>REWIND</scp> cardiovascular disease criteria to <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6: An exploratory analysis of cardiovascular outcomes with semaglutide. Diabetes, Obesity and Metabolism, 2021, 23, 1677-1680.	4.4	4
7	Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the <scp>DEFINEâ€HF</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1426-1430.	4.4	14
8	Roles of vascular endothelial and smooth muscle cells in the vasculoprotective effect of insulin in a mouse model of restenosis. Diabetes and Vascular Disease Research, 2021, 18, 147916412110273.	2.0	4
9	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	27.0	778
10	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	27.0	712
11	Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial. Journal of Medical Economics, 2021, 24, 1318-1326.	2.1	0
12	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes, Obesity and Metabolism, 2020, 22, 442-451.	4.4	102
13	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovascular Diabetology, 2020, 19, 156.	6.8	25
14	Functional culture and in vitro genetic and small-molecule manipulation of adult mouse cardiomyocytes. Communications Biology, 2020, 3, 229.	4.4	8
15	Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clinical Trials, 2020, 17, 491-500.	1.6	56
16	Effects of Liraglutide on CardiovascularÂOutcomes in Patients With Diabetes With or Without HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 1128-1141.	2.8	53
17	Cover Image, Volume 22, Issue 3. Diabetes, Obesity and Metabolism, 2020, 22, .	4.4	0
18	Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-Î±. Journal of Clinical Investigation, 2020, 130, 1392-1404.	8.2	37

#	Article	IF	Citations
19	Incidental COVID-19 on PET/CT imaging. Cmaj, 2020, 192, E631-E631.	2.0	3
20	Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovascular Diabetology, 2019, 18, 156.	6.8	17
21	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2019, 140, 1463-1476.	1.6	279
22	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 841-851.	27.0	1,002
23	c-Myb Exacerbates Atherosclerosis through Regulation of Protective IgM-Producing Antibody-Secreting Cells. Cell Reports, 2019, 27, 2304-2312.e6.	6.4	3
24	CFTR Therapeutics Normalize CerebralÂPerfusion Deficits in MouseÂModels of HeartÂFailure and Subarachnoid Hemorrhage. JACC Basic To Translational Science, 2019, 4, 940-958.	4.1	27
25	Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial. Journal of Cardiac Failure, 2019, 25, 937-938.	1.7	4
26	B-Cell Deficiency Lowers Blood Pressure in Mice. Hypertension, 2019, 73, 561-570.	2.7	23
27	Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. Nature Immunology, 2019, 20, 29-39.	14.5	537
28	Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes, Obesity and Metabolism, 2019, 21, 499-508.	4.4	71
29	Cardiac-specific inducible overexpression of human plasma membrane Ca2+ ATPase 4b is cardioprotective and improves survival in mice following ischemic injury. Clinical Science, 2018, 132, 641-654.	4.3	7
30	Aortic Sca-1⁺Progenitor Cells Arise from the Somitic Mesoderm Lineage in Mice. Stem Cells and Development, 2018, 27, 888-897.	2.1	1
31	Diagnostic and prognostic significance of transient ischemic dilation (TID) in myocardial perfusion imaging: A systematic review and meta-analysis. Journal of Nuclear Cardiology, 2018, 25, 724-737.	2.1	31
32	HDL protects against doxorubicin-induced cardiotoxicity in a scavenger receptor class B type 1-, PI3K-, and Akt-dependent manner. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H31-H44.	3.2	18
33	c-Myb regulates transcriptional activation of miR-143/145 in vascular smooth muscle cells. PLoS ONE, 2018, 13, e0202778.	2.5	9
34	Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA. Current Diabetes Reports, 2018, 18, 45.	4.2	37
35	Skin-derived precursors from human subjects with Type 2 diabetes yield dysfunctional vascular smooth muscle cells. Clinical Science, 2017, 131, 1801-1814.	4.3	2
36	Urinary adenosine excretion in type 1 diabetes. American Journal of Physiology - Renal Physiology, 2017, 313, F184-F191.	2.7	46

#	Article	IF	Citations
37	Diabetes impairs arterio-venous specification in engineered vascular tissues in a perivascular cell recruitment-dependent manner. Biomaterials, 2017, 119, 23-32.	11.4	17
38	A CD103+ Conventional Dendritic Cell Surveillance System Prevents Development of Overt Heart Failure during Subclinical Viral Myocarditis. Immunity, 2017, 47, 974-989.e8.	14.3	50
39	Paradoxical Suppression of Atherosclerosis in the Absence of microRNA-146a. Circulation Research, 2017, 121, 354-367.	4.5	79
40	S-Nitrosoglutathione Reductase Deficiency Confers Improved Survival and Neurological Outcome in Experimental Cerebral Malaria. Infection and Immunity, 2017, 85, .	2.2	13
41	Prognostic impact of SPECT-MPI after renal transplantation. Journal of Nuclear Cardiology, 2017, 24, 295-303.	2.1	3
42	Tumor Necrosis Factor/Sphingosine-1-Phosphate Signaling Augments Resistance Artery Myogenic Tone in Diabetes. Diabetes, 2016, 65, 1916-1928.	0.6	22
43	Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. Diabetes, 2016, 65, 1714-1723.	0.6	87
44	c-Myb Regulates Proliferation and Differentiation of Adventitial Sca1 ⁺ Vascular Smooth Muscle Cell Progenitors by Transactivation of Myocardin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1367-1376.	2.4	25
45	Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus. Circulation, 2016, 134, 752-772.	1.6	932
46	Self-renewing resident arterial macrophages arise from embryonic CX3CR1+ precursors and circulating monocytes immediately after birth. Nature Immunology, 2016, 17, 159-168.	14.5	275
47	Cardiovascular outcomes after pharmacologic stress myocardial perfusion imaging. American Heart Journal, 2016, 174, 138-146.	2.7	4
48	Vascular smooth muscle cell differentiation from human stem/progenitor cells. Methods, 2016, 101, 85-92.	3.8	22
49	Distal coronary embolization following acute myocardial infarction increases early infarct size and late left ventricular wall thinning in a porcine model. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 106.	3.3	9
50	Cardioprotective Signature of Short-Term Caloric Restriction. PLoS ONE, 2015, 10, e0130658.	2.5	47
51	Thioredoxin-Interacting Protein Deficiency Protects against Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 2963-2977.	6.1	80
52	The Antidiabetic Hormone Glucagon-Like Peptide-1 Induces Formation of New Elastic Fibers in Human Cardiac Fibroblasts After Cross-Activation of IGF-IR. Endocrinology, 2015, 156, 90-102.	2.8	14
53	Enhanced proliferation and altered calcium handling in RGS2-deficient vascular smooth muscle cells. Journal of Receptor and Signal Transduction Research, 2014, 34, 476-483.	2.5	5
54	Perlecan Heparan Sulfate Proteoglycan Is a Critical Determinant of Angiogenesis in Response to Mouse Hind-Limb Ischemia. Canadian Journal of Cardiology, 2014, 30, 1444-1451.	1.7	12

#	Article	IF	Citations
55	Calcium Efflux Activity of Plasma Membrane Ca2+ ATPase-4 (PMCA4) Mediates Cell Cycle Progression in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2014, 289, 7221-7231.	3.4	25
56	Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors. Current Atherosclerosis Reports, 2014, 16, 408.	4.8	5
57	p27 Protein Protects Metabolically Stressed Cardiomyocytes from Apoptosis by Promoting Autophagy. Journal of Biological Chemistry, 2014, 289, 16924-16935.	3.4	45
58	Lack of group X secreted phospholipase A2 increases survival following pandemic H1N1 influenza infection. Virology, 2014, 454-455, 78-92.	2.4	21
59	Inhibition of Src Kinase Blocks High Glucoseâ€“Induced EGFR Transactivation and Collagen Synthesis in Mesangial Cells and Prevents Diabetic Nephropathy in Mice. Diabetes, 2013, 62, 3874-3886.	0.6	119
60	Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nature Medicine, 2013, 19, 1166-1172.	30.7	855
61	Serum-free differentiation of functional human coronary-like vascular smooth muscle cells from embryonic stem cells. Cardiovascular Research, 2013, 98, 125-135.	3.8	33
62	A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity. Circulation, 2013, 127, 74-85.	1.6	199
63	Mutation in Integrin-Linked Kinase (ILKR211A) and Heat-Shock Protein 70 Comprise a Broadly Cardioprotective Complex. PLoS ONE, 2013, 8, e77331.	2.5	14
64	The Role of Growth Differentiation Factor 5 in Cardiac Repair Post-Myocardial Infarction. , 2013, , 365-382.		1
65	Proximal Cerebral Arteries Develop Myogenic Responsiveness in Heart Failure via Tumor Necrosis Factor-Î±â€“Dependent Activation of Sphingosine-1-Phosphate Signaling. Circulation, 2012, 126, 196-206.	1.6	62
66	Regulated Expression and Role of c-Myb in the Cardiovascular-Directed Differentiation of Mouse Embryonic Stem Cells. Circulation Research, 2012, 110, 253-264.	4.5	12
67	Cadaveric thoracic trauma management courses for emergency physicians may contribute to improved outcomes. European Journal of Emergency Medicine, 2012, 19, 204-205.	1.1	1
68	GLP-1 receptor agonists: A clinical perspective on cardiovascular effects. Diabetes and Vascular Disease Research, 2012, 9, 95-108.	2.0	78
69	Post-myocardial infarct p27 fusion protein intravenous delivery averts adverse remodelling and improves heart function and survival in rodents. Cardiovascular Research, 2012, 94, 492-500.	3.8	15
70	Tumor Necrosis Factor-Î±â€“Mediated Downregulation of the Cystic Fibrosis Transmembrane Conductance Regulator Drives Pathological Sphingosine-1-Phosphate Signaling in a Mouse Model of Heart Failure. Circulation, 2012, 125, 2739-2750.	1.6	63
71	The Primary Benefits of Angiotensin-Converting Enzyme Inhibition on Cardiac Remodeling Occur During Sleep Time in Murine Pressure Overload Hypertrophy. Journal of the American College of Cardiology, 2011, 57, 2020-2028.	2.8	79
72	Directed Differentiation of Skin-Derived Precursors Into Functional Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2938-2948.	2.4	43

#	Article	IF	Citations
73	Cardiovascular outcomes are predicted by exercise-stress myocardial perfusion imaging: Impact on death, myocardial infarction, and coronary revascularization procedures. American Heart Journal, 2011, 161, 900-907.	2.7	21
74	The Incretin System and Cardiovascular Risk: Effects of Incretin-Targeted Therapies. Current Cardiovascular Risk Reports, 2011, 5, 62-69.	2.0	1
75	Electrical remodelling precedes heart failure in an endothelin-1-induced model of cardiomyopathy. Cardiovascular Research, 2011, 89, 623-633.	3.8	36
76	Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress. Cardiovascular Research, 2011, 92, 375-384.	3.8	72
77	Peptide-Mediated Disruption of Calmodulinâ€“Cyclin E Interactions Inhibits Proliferation of Vascular Smooth Muscle Cells and Neointima Formation. Circulation Research, 2011, 108, 1053-1062.	4.5	19
78	Sepsis-induced myocardial depression is associated with transcriptional changes in energy metabolism and contractile related genes: A physiological and gene expression-based approach*. Critical Care Medicine, 2010, 38, 894-902.	0.9	67
79	Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor. Endocrinology, 2010, 151, 1520-1531.	2.8	194
80	Sphingosine-1-Phosphateâ€“Dependent Activation of p38 MAPK Maintains Elevated Peripheral Resistance in Heart Failure Through Increased Myogenic Vasoconstriction. Circulation Research, 2010, 107, 923-933.	4.5	66
81	Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice. Diabetes, 2010, 59, 1063-1073.	0.6	249
82	Temporal and Spatial Regulation of Histone Deacetylase-7 and Î²-Catenin in Endothelial Cells. Circulation Research, 2010, 106, 1180-1183.	4.5	1
83	Spontaneous Adult-Onset Pulmonary Arterial Hypertension Attributable to Increased Endothelial Oxidative Stress in a Murine Model of Hereditary Hemorrhagic Telangiectasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 509-517.	2.4	47
84	Growth Differentiation Factor 5 Regulates Cardiac Repair After Myocardial Infarction. Journal of the American College of Cardiology, 2010, 55, 135-143.	2.8	37
85	Cardiomyocyte-targeted overexpression of the coxsackieâ€“adenovirus receptor causes a cardiomyopathy in association with Î²-catenin signaling. Journal of Molecular and Cellular Cardiology, 2010, 48, 1194-1205.	1.9	29
86	Generation of human embryonic stem cellâ€derived mesoderm and cardiac cells using sizeâ€specified aggregates in an oxygenâ€controlled bioreactor. Biotechnology and Bioengineering, 2009, 102, 493-507.	3.3	211
87	GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice. Diabetes, 2009, 58, 975-983.	0.6	491
88	Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretinâ€”based therapies. Journal of the American Society of Hypertension, 2009, 3, 245-259.	2.3	63
89	Control of Human Embryonic Stem Cell Colony and Aggregate Size Heterogeneity Influences Differentiation Trajectories. Stem Cells, 2008, 26, 2300-2310.	3.2	419
90	Electrogram fractionation in murine HL-1 atrial monolayer model. Heart Rhythm, 2008, 5, 1029-1035.	0.7	41

#	Article	IF	Citations
91	Region-specific patterns of vascular remodelling occur early in atherosclerosis and without loss of smooth muscle cell markers. Atherosclerosis, 2008, 196, 617-623.	0.8	7
92	Diurnal profiling of neuroendocrine genes in murine heart, and shift in proopiomelanocortin gene expression with pressure-overload cardiac hypertrophy. Journal of Molecular Endocrinology, 2008, 41, 117-124.	2.5	26
93	c-Mybâ€“Dependent Smooth Muscle Cell Differentiation. Circulation Research, 2008, 102, 554-561.	4.5	39
94	Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptorâ€“Dependent and â€“Independent Pathways. Circulation, 2008, 117, 2340-2350.	1.6	885
95	c-Mybâ€“Dependent Inositol 1,4,5-Trisphosphate Receptor Type-1 Expression in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1305-1311.	2.4	14
96	A Candidate Hypertension Gene. Circulation Research, 2007, 100, 940-942.	4.5	6
97	Vascular Smooth Muscle Cells: The Muscle behind Vascular Biology. , 2007, , 545-561.		0
98	Introductory Essay: Diagnosis and Treatment. , 2007, , 1599-1601.		0
99	Calmodulin-Mediated Cell Cycle Regulation: New Mechanisms for Old Observations. Cell Cycle, 2006, 5, 2183-2186.	2.6	40
100	A Calmodulin-Binding Site on Cyclin E Mediates Ca 2+ -Sensitive G 1 /S Transitions in Vascular Smooth Muscle Cells. Circulation Research, 2006, 98, 1273-1281.	4.5	45
101	Integrin-Linked Kinase Expression Is Elevated in Human Cardiac Hypertrophy and Induces Hypertrophy in Transgenic Mice. Circulation, 2006, 114, 2271-2279.	1.6	116
102	Effect of Vasopressin on Hemodynamics in Patients With Refractory Cardiogenic Shock Complicating Acute Myocardial Infarction. American Journal of Cardiology, 2005, 96, 1617-1620.	1.6	86
103	Electrocardiographic prediction of the severity of posterior wall perfusion defects on rest technetium-99m Sestamibi myocardial perfusion imaging. Journal of Electrocardiology, 2005, 38, 195-203.	0.9	1
104	Myeloid Differentiation Factor-88 Plays a Crucial Role in the Pathogenesis of Coxsackievirus B3â€“Induced Myocarditis and Influences Type I Interferon Production. Circulation, 2005, 112, 2276-2285.	1.6	163
105	A Role for Endoglin in Coupling eNOS Activity and Regulating Vascular Tone Revealed in Hereditary Hemorrhagic Telangiectasia. Circulation Research, 2005, 96, 684-692.	4.5	225
106	Increased Fibulin-5 and Elastin in S100A4/Mts1 Mice With Pulmonary Hypertension. Circulation Research, 2005, 97, 596-604.	4.5	87
107	The role of endothelin-1 in myocarditis and inflammatory cardiomyopathy: old lessons and new insights. Canadian Journal of Physiology and Pharmacology, 2005, 83, 47-62.	1.4	18
108	The Homeodomain Transcription Factor Irx5 Establishes the Mouse Cardiac Ventricular Repolarization Gradient. Cell, 2005, 123, 347-358.	28.9	233

#	Article	IF	Citations
109	Troubles With a Transgene: Experiences With SM22Î±-tTA Mice. Circulation Research, 2005, 97, .	4.5	1
110	Elafin-overexpressing mice have improved cardiac function after myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H286-H292.	3.2	37
111	Conditional Cardiac Overexpression of Endothelin-1 Induces Inflammation and Dilated Cardiomyopathy in Mice. Circulation, 2004, 109, 255-261.	1.6	155
112	From molecules to mammals: what's NOS got to do with it?. Acta Physiologica Scandinavica, 2003, 179, 123-135.	2.2	134
113	Conditional Expression of a Dominant-Negative c-Myb in Vascular Smooth Muscle Cells Inhibits Arterial Remodeling After Injury. Circulation Research, 2003, 92, 314-321.	4.5	40
114	Plasma Membrane Calcium ATPase Overexpression in Arterial Smooth Muscle Increases Vasomotor Responsiveness and Blood Pressure. Circulation Research, 2003, 93, 614-621.	4.5	82
115	Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor. Endocrinology, 2003, 144, 2242-2252.	2.8	182
116	The Iroquois Homeobox Gene Irx2 Is Not Essential for Normal Development of the Heart and Midbrain-Hindbrain Boundary in Mice. Molecular and Cellular Biology, 2003, 23, 8216-8225.	2.3	49
117	Calcineurin-independent regulation of plasma membrane Ca²⁺ATPase-4 in the vascular smooth muscle cell cycle. American Journal of Physiology - Cell Physiology, 2003, 285, C88-C95.	4.6	49
118	Differential Regulation of Gonadotropin-Releasing Hormone Secretion and Gene Expression by Androgen: Membrane Versus Nuclear Receptor Activation. Molecular Endocrinology, 2002, 16, 2592-2602.	3.7	50
119	Overexpression of the Serine Elastase Inhibitor Elafin Protects Transgenic Mice From Hypoxic Pulmonary Hypertension. Circulation, 2002, 105, 516-521.	1.6	162
120	Reversible regional wall motion abnormalities on exercise technetium-99mâ€“gated cardiac single photon emission computed tomography predict high-grade angiographic stenoses. Journal of the American College of Cardiology, 2002, 39, 991-998.	2.8	112
121	Effects of age, gender, and blood pressure on myogenic responses of mesenteric arteries from C57BL/6 mice. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H380-H388.	3.2	75
122	The role of NOS in heart failure: lessons from murine genetic models. Heart Failure Reviews, 2002, 7, 407-422.	3.9	77
123	Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. Journal of Clinical Investigation, 2002, 109, 735-743.	8.2	220
124	Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. Journal of Clinical Investigation, 2002, 109, 735-743.	8.2	132
125	Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 7469-7474.	7.1	93
126	c-Myb-binding Sites Mediate G1/S-associated Repression of the Plasma Membrane Ca2+-ATPase-1 Promoter. Journal of Biological Chemistry, 2000, 275, 9062-9069.	3.4	35

#	Article	IF	Citations
127	Suppressed smooth muscle proliferation and inflammatory cell invasion after arterial injury in elafin-overexpressing mice. Journal of Clinical Investigation, 2000, 105, 1687-1695.	8.2	45
128	Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis. Journal of Clinical Investigation, 1999, 103, 1211-1219.	8.2	51
129	Vascular Antisense Therapy Directed Against c-myc, c-myb and PCNA. Perspectives in Antisense Science, 1999, , 71-98.	0.2	0
130	c-Myb function in fibroblasts. , 1997, 173, 319-326.		19
131	c-Mybâ€"Dependent Cell Cycle Progression and Ca 2+ Storage in Cultured Vascular Smooth Muscle Cells. Circulation Research, 1997, 80, 617-626.	4.5	32
132	Targeting of Transgene Expression to the Vascular Endothelium of Mice by Homologous Recombination at the Thrombomodulin Locus. Circulation Research, 1996, 78, 180-187.	4.5	40
133	A possible escape phenomenon of lipoprotein(a) in sustained plasma exchange. Transfusion Science, 1993, 14, 417-421.	0.6	0